The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53

NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner

(2009) Y.-X. Cui et al.   BLOOD

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma

(2009) E Drakos et al.   LEUKEMIA

p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism

(2008) A. J. Steele et al.   BLOOD

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5

(2008) B. Z. Carter et al.   BLOOD

ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project

(2008) K. J. Savage et al.   BLOOD

MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2

(2008) L Gu et al.   LEUKEMIA

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

(2008) M Kitagawa et al.   ONCOGENE